Aduhelm OK 'bit­ter­sweet' for ALS ad­vo­cates; Con­trast­ing Covid-19 vac­cine read­outs; GSK joins TIG­IT bat­tle; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

With the busiest days of June now be­hind us, we’re start­ing to think se­ri­ous­ly about the sec­ond half of the year. In Au­gust, we have sched­uled a spe­cial re­port where End­points will com­pile a list of the 20 most in­flu­en­tial R&D ex­ec­u­tives in bio­phar­ma. Know a lu­mi­nary who should def­i­nite­ly be in­clud­ed? Nom­i­nate them now.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.